GDNF used in experiments with rats for alcoholism research
 

http://living.health.com/2008/06/10/...sive-drinking/

New Treatment Shows Promise for Excessive Drinking


TUESDAY, June 10 (HealthDay News) — A new treatment that reduces excessive drinking and prevents drinking relapse proved successful in tests on rats, a new study finds.

The treatment involves increasing levels of a brain protein called glial cell-derived neurotrophic factor (GDNF) — also being looked at as a treatment for Parkinson’s disease. The researchers also pinpointed the site in the brain where GDNF acts to control drinking.

In addition, the treatment didn’t block other normal pleasure-seeking behaviors (such as craving sweets), a common problem with drugs developed to treat alcoholism.

In this study, rats were conditioned for two months to seek alcohol. The researchers then injected GDNF into a brain region called the Ventral Tegmental Area (VTA), which is believed to be strongly involved in drug-seeking behavior. The rats’ desire to drink alcohol decreased significantly within as little as 10 minutes, and the effect lasted at least three hours.

But the rats still wanted to drink sugar water after the injections of GDNF, which shows that increased levels of GDNF didn’t decrease this pleasure-seeking behavior.

In another part of the study, the researchers trained rats to desire alcohol and then took it away from them. When alcohol was reintroduced, the rats started drinking the same amount as before. But when they were treated with GDNF, they lost their taste for alcohol.

The study was published in this week’s issue of the Proceedings of the National Academy of Sciences.

“Alcoholism is a devastating and costly psychiatric disease with enormous socioeconomic impact. There is tremendous need for therapies to treat alcohol abuse,” study senior author Dorit Ron, principal investigator at the University of California, San Francisco-affiliated Ernest Gallo Clinic and Research Center, said in a prepared statement.

“Unfortunately, only three drugs are currently approved to treat excessive drinking, and all have serious limitations. Our findings open the door to a promising new strategy to combat alcohol abuse, addiction and especially relapse,” Ron said.

More information

The American Psychological Association has more about alcohol use disorders and their treatment.


– Robert Preidt

SOURCE: University of California, San Francisco, news release, June 9, 2008

Last Updated: June 10, 2008

Copyright © 2008 ScoutNews, LLC. All rights reserved.

Thanks for this, Madelyn. Wouldn't it be ironic if this research kicked Amgen's b*** off their self-serving seats, considering the much greater incidence of alcoholism and its real social and economic costs? Hope springs eternal.
Robert

But wait! isn't Amgen funding this trial?
 

My understanding is that Amgen holds the patent for the injected GDNF-that's why no one else could offer it to those poor souls in the PD/GDNF trial when it was withdrawn. So they must be allowing this trial to be conducted, right? And if they are allowing their patented product to be used in this trial, aren't they probably paying for the trial as well? Why would they fund another trial of the same product that requires the same delivery method they found "too difficult" and "objectionable" before?

And if they don't have a patent on the injected GDNF, why hasn't some other pharma come forward long before now and used GDNF, picking up where AmGen cut everyone off in that earlier fiasco?

How badly do I have my information?

I heard ...
 

"GDNF" was about to be sold (don't know if thats the patent or the right to use it), and that the chaps in Bristol UK have developed a new delivery mechanism to test.

Of course I may have just imagined it :)

Neil.